# POIESIS (NCT06479135)

> Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06479135
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Kartos Therapeutics, Inc.
- Conditions: Myelofibrosis; Post-PV MF; Post-ET Myelofibrosis; Primary Myelofibrosis; MF
- Interventions: Navtemadlin; Navtemadlin placebo; Ruxolitinib
- Enrollment: 600
- Primary outcome: To compare spleen volume reduction (SVR35) between Arm 1 and Arm 2
- Primary outcome: To compare total symptom score reduction (TSS50) between Arm 1 and Arm 2

## Commentary we found

- YouTube: 9
- Podcasts: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=poiesis-nct06479135

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06479135", "email": "<work email>"}; the inbox owner confirms by the emailed link.